Product Name:    Clascoterone

Synonyms:    17alpha-propionate;CB-03-1;17alpha-propio17-(1-oxopropoxy)pregn-4-ene-3,20-dione;CB-03-01 17alpha-propionate;CB-03-01;Cortexolone 17-alpha-propionate;17 alpha-propionate (CB-03-01);21-Hydroxy-17-(1-oxopropoxy)pregn-4-ene-3,20-dione

CAS:    19608-29-8

MF:    C24H34O5

MW:    402.52

EINECS:    685-282-9

Product Categories:    APIS;API;19608-29-8

Clascoterone (Winlevi?) is an androgen receptor inhibitor being developed as a topical cream and solution by Cassiopea (a spin-out company of Cosmo Pharmaceuticals) for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. Although the exact mechanism of action of clascoterone for the topical treatment of acne vulgaris is unknown, the drug is believed to compete with the androgen dihydrotestosterone for binding to androgen receptors in the sebaceous gland and hair follicles to attenuate signalling necessary for acne pathogenesis. In August 2020, clascoterone cream 1% received its first approval in the USA for the topical treatment of acne vulgaris in patients 12 years of age or older. Clinical studies of a different formulation of clascoterone (a solution containing a higher concentration of the drug) for the treatment of androgenetic alopecia are underway in Germany and the USA. This article summarizes the milestones in the development of clascoterone leading to this first approval for the topical treatment of acne vulgaris.